Literature DB >> 32086685

Elevated cerebrospinal fluid homocysteine is associated with blood-brain barrier disruption in amyotrophic lateral sclerosis patients.

Yonghua Wu1, Xu Yang1, Xiaogang Li2, Haining Wang3, Tiancheng Wang4.   

Abstract

OBJECTIVES: Homocysteine (Hcy) has been shown to be relevant in the pathogenesis of amyotrophic lateral sclerosis (ALS). Although the CSF Hcy changes were explored in patients with ALS previously, the outcomes were inconsistent, and the permeability of the blood-brain barrier (BBB) may involve in the process. The aim of this study was to investigate the relationship between concentration of Hcy and BBB integrity indicated by CSF/serum albumin ratio (Qalb).
METHODS: CSF and plasma/serum levels of Hcy, folate, and vitamin B12 and other biochemical biomarkers such as albumin, β2-microglobulin, high sensitive-C reactive protein (hs-CRP), microalbumin, immunoglobulin G (IgG), IgM, IgA, and complement 3 and 4 were analyzed in all 31 ALS patients and 34 controls. Routine CSF analysis including cells/leukocytes count, total protein, glucose, and chlorides were also performed.
RESULTS: CSF Hcy levels (0.50 ± 0.46 vs 0.25 ± 0.27 μmol/L) and Qalb (8.09 ± 3.03 vs 6.39 ± 2.21) were significantly higher in the ALS group than that in controls (P < 0.05). The generalized linear mixed model analysis showed that the CSF Hcy was positively correlated with Qalb in ALS patients (P < 0.05).
CONCLUSIONS: BBB permeability is increased in ALS patients. CSF Hcy level is associated with BBB integrity. Qalb is a significantly independent predisposing factor for CSF Hcy.

Entities:  

Keywords:  Amyotrophic lateral sclerosis; Blood-brain barrier; Folate; Homocysteine; Q-albumin; Vitamin B12

Mesh:

Substances:

Year:  2020        PMID: 32086685     DOI: 10.1007/s10072-020-04292-x

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  5 in total

1.  Cognitive impairment persists at least 1 year after juvenile rats are treated with methotrexate.

Authors:  Jing Wen; Chadni Patel; Frank Diglio; Kayla Baker; Gregory Marshall; Shengguo Li; Peter D Cole
Journal:  Neuropharmacology       Date:  2022-01-02       Impact factor: 5.250

2.  Aberrations of biochemical indicators in amyotrophic lateral sclerosis: a systematic review and meta-analysis.

Authors:  Yangfan Cheng; Yongping Chen; Huifang Shang
Journal:  Transl Neurodegener       Date:  2021-01-08       Impact factor: 8.014

3.  Breached Barriers: A Scoping Review of Blood-Central Nervous System Barrier Pathology in Amyotrophic Lateral Sclerosis.

Authors:  Ario Mirian; Alexander Moszczynski; Serena Soleimani; Isabelle Aubert; Lorne Zinman; Agessandro Abrahao
Journal:  Front Cell Neurosci       Date:  2022-03-31       Impact factor: 5.505

Review 4.  Neuroimmune Crosstalk Between the Peripheral and the Central Immune System in Amyotrophic Lateral Sclerosis.

Authors:  Weiyi Yu; Ji He; Xiying Cai; Zhou Yu; Zhangyu Zou; Dongsheng Fan
Journal:  Front Aging Neurosci       Date:  2022-05-03       Impact factor: 5.750

Review 5.  Altered TDP-43 Structure and Function: Key Insights into Aberrant RNA, Mitochondrial, and Cellular and Systemic Metabolism in Amyotrophic Lateral Sclerosis.

Authors:  Leanne Jiang; Shyuan T Ngo
Journal:  Metabolites       Date:  2022-07-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.